3 Oncology Specialist, Respiratory and Global Generics Leader and Active Ingredients Maker Stocks With a Strong Future Roadmap: Natco Pharma, Cipla and Granules India
- October 26, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Natco Pharma, Cipla and Granules India: ROE of 11.3% to 15.4% and FY22 to FY26 revenue CAGR of 7.1% to 21.0%. Prices as of 23 Oct 2026.
Quick Answer
The three oncology, respiratory and API pharma stocks to watch are Natco Pharma, Cipla and Granules India. Their return on equity ranges from 11.3% to 15.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 21.0%. Natco Pharma leads on both return on equity at 15.4% and revenue growth at 21.0% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Oncology, respiratory and API pharma stocks let investors follow companies that serve a growing part of the Indian economy. Natco Pharma, Cipla and Granules India cover an oncology specialist, a respiratory and global generics leader and an active ingredients maker.
This list covers three oncology, respiratory and API pharma stocks with complete current figures: Natco Pharma, Cipla and Granules India. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Oncology, Respiratory and API Pharma Stocks?
Oncology, respiratory and API pharma stocks are listed drug makers that focus on cancer care, respiratory medicines and active pharmaceutical ingredients. Their earnings depend on new launches, regulatory approvals, pricing and plant quality.
Oncology, Respiratory and API Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Natco Pharma | 791.85 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
| Cipla | 1,338 | 107,528 | 32.0 | 36.0 | 11.3 | 0.02 |
| Granules India | 794.75 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing oncology, respiratory and API pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Oncology, Respiratory and API Pharma Stocks Have a Strong Roadmap in India?
Oncology, respiratory and API pharma stocks have a strong roadmap in India because specialty therapies, trusted respiratory brands and a growing ingredient supply chain keep lifting demand for Indian drug makers.
- Specialty therapies. Cancer care and complex drugs earn better margins.
- Respiratory care. Inhalers and asthma drugs have loyal users.
- Ingredient supply. Global makers diversify sourcing of active ingredients.
Why Natco Pharma Features Among These Oncology, Respiratory and API Pharma Stocks
Among the oncology, respiratory and API pharma stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Why Cipla Features Among These Oncology, Respiratory and API Pharma Stocks
Among the complex generics company shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.
In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%.
Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.
Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What to watch: Follow new product launches in the United States and the growth of key domestic brands.
Why Granules India Features Among These Oncology, Respiratory and API Pharma Stocks
Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Natco Pharma vs Cipla vs Granules India on Key Financials
The table below sets the three oncology, respiratory and API pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
| Cipla | 22,044 | 29,045 | 7.1% | 3,870 | 13.3% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
Natco Pharma posts the highest return on equity in this group at 15.4%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with oncology, respiratory and API pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Oncology, Respiratory and API Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these oncology, respiratory and API pharma stocks, the main points are:
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices abroad can fall.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter oncology, respiratory and API pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Oncology, Respiratory and API Pharma Stocks
Oncology, respiratory and API pharma stocks reward investors who follow demand trends, order books and margins together. Natco Pharma, Cipla and Granules India each have a clear plan to grow. Based on the 23 October 2026 close, Natco Pharma trades at Rs 791.85, Cipla at Rs 1,338 and Granules India at Rs 794.75.
Download the Univest iOS App or Univest Android App to track oncology, respiratory and API pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are oncology, respiratory and API pharma stocks?
Ans. Oncology, respiratory and API pharma stocks are listed drug makers that focus on cancer care, respiratory medicines and active pharmaceutical ingredients. Their earnings depend on new launches, regulatory approvals, pricing and plant quality. This list looks at three of them, Natco Pharma, Cipla and Granules India, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which oncology, respiratory and API pharma stocks are covered in this list?
Ans. This list covers Natco Pharma, Cipla and Granules India. Based on the 23 October 2026 close, Natco Pharma traded at Rs 791.85, Cipla at Rs 1,338 and Granules India at Rs 794.75. Their return on equity ranges from 11.3% to 15.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 21.0%.
Why do oncology, respiratory and API pharma stocks have a strong future roadmap in India?
Ans. Oncology, respiratory and API pharma stocks have a strong roadmap in India because specialty therapies, trusted respiratory brands and a growing ingredient supply chain keep lifting demand for Indian drug makers. The main drivers are as follows. Specialty therapies. Cancer care and complex drugs earn better margins. Respiratory care. Inhalers and asthma drugs have loyal users. Ingredient supply. Global makers diversify sourcing of active ingredients. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
How has Cipla performed financially?
Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What risks should investors check before buying oncology, respiratory and API pharma stocks?
Ans. Investors should check a few risks before buying oncology, respiratory and API pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of oncology, respiratory and API pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
